40.Massardo L., Suarez-Almazor M.E., Cardiel M.H. et al. Management of patients with rheumatoid arthritis in Latin America: A consensus position paper from Pan-American League of Associations of Rheumatology and Grupo Latino Americano De Estudio De Artritis Reumatoide. J.Clin. Rheumatol .,2009,15,203-
41.Smolen J.S., Keystone E.C., Emery P. et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis [review]. Ann. Rheum. Dis
.,2007,66,143-50.
42.Smolen J.S., Landewe R., Breedveld F.C. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological diseasemodifying antirheumatic drugs. Ann. Rheum. Dis., 2010,69,964-75.
43.British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax., 2005,60,800-5.
44.Mazurek G.H., Jereb J., Vernon A. et al.Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection — United States,2010. MMWR Recomm.Rep., 2010,59:1-25.
45. Fautrel B., Pham T., Mouterde G. et al. Recommendations of the French Society for Rheumatology regarding TNF alpha antagonist therapy in patients with rheumatoid arthritis. Joint Bone Spine, 2007,74,627-37.
46.Misra R., Sharma B.L., Gupta R. et al. Indian Rheumatology Association consensus statement on themanagement of adults with rheumatoid arthritis. Indian J. Rheumatol., 2008,3, Suppl.,S1-S16.
47. van Assen S., Agmon-Levin N., Elkayam O. et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann. Rheum. Dis., 2011,70,414-22.
48. Soriano E.R., Galarza-Maldonado C., Cardiel M.H. et al. Use of rituximab for the treatment of rheumatoid arthritis: The Latin American context.Rheumatology, 2008,47,1097-9.